Recovery Cone Removal System

K152136 · C.R. Bard, Inc. · MMX · Feb 18, 2016 · Cardiovascular

Device Facts

• Record ID: K152136
• Device Name: Recovery Cone Removal System
• Applicant: C.R. Bard, Inc.
• Product Code: MMX · Cardiovascular
• Decision Date: Feb 18, 2016
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.5150
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

RC-15 Model: The Recovery Cone Removal System is intended for use to percutaneously remove the Recovery Filter, Recovery G2 Filter and G2 X Filter from the vena cava. FBRC Model: The Recovery Cone Removal System is intended for use to percutaneously remove the G2 X Filter, G2 Express Filter, G2 Filter and the Recovery Filter from the vena cava, or facilitate the retrieval of foreign objects from the peripheral vascular system.

Device Story

Percutaneous retrieval system for vena cava filters and foreign objects; consists of reinforced urethane cone (15-mm diameter) with wire claws, Pebax shaft, handle, and 10 French introducer sheath/dilator. Operates over 0.035" guidewire; Touhy-Borst Y-adapter allows saline flush. Used in clinical/interventional settings by physicians. Device engages target object via cone/claws, then withdraws into outer sheath for removal. Fluoroscopic visualization aided by radiopaque markers. Benefits patient by enabling minimally invasive removal of filters or foreign bodies, reducing need for open surgery.

Clinical Evidence

Bench testing included tensile, leak, torque, and simulated use testing. Biocompatibility testing performed per ISO 10993 (cytotoxicity, sensitization, irritation, acute systemic toxicity, pyrogenicity, hemocompatibility, thromboresistance, coagulation). In-vivo animal testing and clinical references evaluated filter capture and retrieval performance.

Technological Characteristics

Reinforced urethane cone (15-mm) with wire claws; Pebax shaft; 10 French introducer sheath/dilator; radiopaque markers for fluoroscopy. Compatible with 0.035" guidewire. Sterile, single-use. Biocompatibility per ISO 10993 standards.

Indications for Use

Indicated for percutaneous removal of specific vena cava filters (Recovery, Recovery G2, G2 X, G2 Express) or retrieval of foreign objects from the peripheral vascular system.

Regulatory Classification

Identification

An embolectomy catheter is a balloon-tipped catheter that is used to remove thromboemboli, i.e., blood clots which have migrated in blood vessels from one site in the vascular tree to another.

Predicate Devices

• Cook FourSnare Vascular Retrieval Snare (K112185)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized human figure in profile, with three overlapping faces suggesting community and support.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

February 18, 2016

Bard Peripheral Vascular, Inc. Ms. Joni Creal Regulatory Affairs Program Manager 1625 West 3rd Street Tempe, Arizona 85281

Re: K152136

Trade/Device Name: Recovery Cone® Removal System Regulation Number: 21 CFR 870.5150 Regulation Name: Embolectomy Catheter Regulatory Class: Class II Product Code: MMX Dated: December 29, 2015 Received: January 05, 2016

Dear Ms. Creal:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Kenneth J. Cavanaugh -S

for

Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K152136

Device Name Recovery Cone® Removal System

#### Indications for Use (Describe)

RC-15 Model: The Recovery Cone Removal System is intended for use to percutaneously remove the Recovery Filter, Recovery G2 Filter and G2 X Filter from the vena cava.

FBRC Model: The Recovery Cone Removal System is intended for use to percutaneously remove the G2 X Filter, G2 Express Filter, G2 Filter and the Recovery Filter from the vena cava, or facilitate the retrieval of foreign objects from the peripheral vascular system.

| Type of Use (Select one or both, as applicable) | |
|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| <div> <span> </span> Prescription Use (Part 21 CFR 801 Subpart D) </div> | <div> <span> </span> Over-The-Counter Use (21 CFR 801 Subpart C) </div> |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

## Recovery Cone® Removal System 510(k) Summary

#### Submitter Information:

| Applicant: | Bard Peripheral Vascular, Inc<br>1625 West 3rd Street<br>Tempe, Arizona 85281 |
|------------|-------------------------------------------------------------------------------|
| Phone: | 480-638-2906 |
| Fax: | 480-449-2546 |
| Contact: | Joni Creal, Regulatory Affairs Program Manager |
| Date: | July 30, 2015 |

#### Subject Device Name:

| Device Trade Name: | Recovery Cone® Removal System |
|-----------------------|--------------------------------|
| Common or Usual Name: | Device, Percutaneous Retrieval |
| Classification: | Class II |
| Review Panel: | Cardiovascular Devices |
| Product Code: | MMX |

#### Cook FourSnare Vascular Retrieval Snare (K112185) Predicate Devices:

#### Device Description:

The Recovery Cone® Removal System is intended to percutaneously remove the G2® X Filter, G2® Express™ Filter, G2® Filter or Recovery® Filter from the vena cava or facilitate the retrieval of foreign objects from the peripheral vascular system. The device is provided sterile and is single use only. The Recovery Cone® Removal System consists of the Removal Cone and Introducer Catheter. The cone consists of a reinforced urethane cone. 15-mm in diameter. The cone is connected to a plastic (Pebax) shaft and handle. The shaft has a central lumen that accommodates a 0.035" guidewire. A Touhy-Borst Y-adapter is used to connect the cone to the Introducer Catheter and to a saline flush or drip. The Introducer Catheter consists of a 10 French

Image /page/3/Picture/12 description: The image shows the word "BARD" in a stylized, sans-serif font. The letters are bold and outlined in black, giving them a distinct and modern appearance. The font choice and design create a visually appealing and recognizable logo or wordmark.

{4}------------------------------------------------

I.D. introducer sheath and dilator. The introducer sheath has a radiopaque marker for enhanced fluoroscopic visualization.

### Indications for Use of Device:

RC-15 Model: The Recovery Cone Removal System is intended for use to percutaneously remove the Recovery Filter, Recovery G2 Filter and G2 X Filter from the vena cava.

FBRC Model: The Recovery Cone Removal System is intended for use to percutaneously remove the G2 X Filter, G2 Express Filter, G2 Filter and the Recovery Filter from the vena cava, or facilitate the retrieval of foreign objects from the peripheral vascular system.

### Technological Comparison to Predicate Devices:

The technological characteristics of the subject device, Recovery Cone® Removal System, are substantially equivalent to the legally marketed predicate device, the Cook FourSnare Retrieval Snare, in terms of intended use, indications for use, operating principle and fundamental scientific technology. Both devices are catheter based systems that have collapsible wires for filter engagement and withdraw into an outer sheath. Both systems are designed to be used over a quidewire. Both devices contain marker bands for visibility. The predicate device contains four wire loops to engage the foreign objects while the Recovery Cone® utilized a urethane cone reinforced with wire claws. The predicate wire loop system is designed to advance through a 80cm, 10 French introducer catheter, and the subject device cone is designed to advance through a 75 cm, 10 French I.D. introducer catheter.

#### Performance Testing Summary:

To demonstrate substantial equivalence of the subject device to the predicate device, the technological characteristics and performance criteria were evaluated using in-vitro testing as outlined below. In addition, the ability to capture the filter and retrieve the filter was evaluated in in-vivo animal testing and within clinical references.

- In-Vitro Filter .
- Tensile

Image /page/4/Picture/13 description: The image shows the word "BARD" in a stylized, all-caps font. The letters are bold and outlined in black, giving them a strong, graphic appearance. The font choice is geometric and modern, with sharp angles and clean lines. The overall design is simple yet impactful, making the word easily recognizable.

{5}------------------------------------------------

- | Leak Test
- Filter Retrieval ।
- -Foreign Body Retrieval
- Sheath and Dilator Tensile, Torque and Leak Integrity Test -
- Catheter Simulated Use Test -
- Marker Band Integrity —
- -Filter Removal Force
- Biocompatibility, per ISO 10993 ●
- Cytotoxicity (ISO 10993-5) -
- Sensitization (ISO 10993-10) |
- -Irritation - Intracutaneous Reactivity (ISO10993-10)
- Acute Systemic Toxicity (ISO10993-11) -
- -Pyrogenicity (ISO 10993-11)
- Hemocompatibility —
- Thromboresistance -
- Coagulation (ISO 10993-4) |

In conclusion, the results of these tests provide reasonable assurance that the device is substantially equivalent to the predicate device.